UP!
| 2016-05-17 | Boost Price Target | Leerink Swann | Outperform | $6.00 to $15.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-02-26 | Reiterated Rating | Leerink Swann | Outperform | $31.00 to $15.00 |
| 2016-02-12 | Downgrade | Bank of America | Neutral to Underperform | $6.00 |
| 2016-02-12 | Downgrade | Bank of America Corp. | Neutral to Underperform | $6.00 |
| 2016-01-11 | Reiterated Rating | Cowen and Company | Market Perform | $15.00 |
| 2015-12-21 | Upgrade | Guggenheim | Sell to Buy | $7.00 to $13.00 |
| 2015-11-17 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-11-11 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $24.00 |
| 2015-11-11 | Upgrade | Bank of America | Underperform to Neutral | $21.00 to $13.00 |
| 2015-11-10 | Lower Price Target | Leerink Swann | Outperform | $38.00 to $31.00 |
| 2015-11-10 | Lower Price Target | Jefferies Group | Buy | $26.00 to $16.00 |
| 2015-11-10 | Lower Price Target | Guggenheim | $9.00 to $7.00 | |
| 2015-11-10 | Reiterated Rating | Cowen and Company | Hold | $25.00 to $15.00 |
| 2015-08-06 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $24.00 |
| 2015-07-28 | Reiterated Rating | Leerink Swann | Outperform | $38.00 |
| 2015-07-28 | Upgrade | Jefferies Group | Hold to Buy | $26.00 |
| 2015-07-27 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | |
| 2015-07-06 | Downgrade | Guggenheim | Neutral to Sell | |
| 2015-05-26 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2015-05-05 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $24.00 |
| 2015-02-27 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $24.00 |
| 2015-01-12 | Reiterated Rating | JPMorgan Chase & Co. | Hold | |
| 2014-10-31 | Downgrade | Bank of America | Buy to Underperform | |
| 2014-10-31 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2014-10-31 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | $24.00 to $43.00 |
| 2014-10-31 | Downgrade | Deutsche Bank | Buy to Hold | $58.00 to $26.00 |
| 2014-10-31 | Downgrade | Jefferies Group | Buy to Hold | $61.00 to $24.00 |
| 2014-10-31 | Downgrade | Deutsche Bank AG | Buy to Hold | $58.00 to $26.00 |
| 2014-10-16 | Downgrade | Bank of America | Buy | |
| 2014-08-15 | Reiterated Rating | Deutsche Bank | Buy | $70.00 to $58.00 |
| 2014-05-27 | Initiated Coverage | Goldman Sachs | Sell | $27.00 |
| 2014-05-07 | Reiterated | FBR Capital | Outperform | $111 to $107 |
| 2014-05-07 | Downgrade | Citigroup Inc. | Outperform to Market Perform | |
| 2014-05-07 | Lower Price Target | Deutsche Bank | $115.00 to $70.00 | |
| 2014-05-07 | Downgrade | Cowen and Company | Outperform to Market Perform | $85.00 to $36.00 |
| 2014-05-07 | Lower Price Target | FBR & Co. | Outperform | $111.00 to $107.00 |
| 2014-05-07 | Lower Price Target | Jefferies Group | $80.00 to $61.00 | |
| 2014-04-21 | Upgrade | Ned Davis Research | Sell to Neutral | |
| 2014-03-28 | Lower Price Target | Jefferies Group | Buy | $90.00 to $80.00 |
| 2014-03-20 | Lower Price Target | Leerink Swann | $86.00 to $66.00 | |
| 2014-03-19 | Lower Price Target | Cowen and Company | $95.00 to $85.00 | |
| 2014-01-10 | Lower Price Target | Cowen and Company | $105.00 to $95.00 | |
| 2013-11-19 | Reiterated Rating | Canaccord Genuity | Buy | $110.00 |
| 2013-11-19 | Reiterated Rating | Leerink Swann | Outperform | $106.00 |
| 2013-11-13 | Boost Price Target | Deutsche Bank | Buy | $107.00 to $115.00 |
| 2013-10-31 | Boost Price Target | Jefferies Group | Buy | $92.00 to $102.00 |
| 2013-10-31 | Boost Price Target | Cowen and Company | Outperform | $105.00 |
| 2013-10-30 | Initiated Coverage | FBR & Co. | Outperform | $105.00 to $111.00 |
| 2013-07-31 | Reiterated | Canaccord Genuity | Buy | $90 to $110 |
| 2013-07-30 | Reiterated | Needham | Buy | $100 |
| 2013-07-22 | Reiterated | Needham | Buy | $50 to $100 |
| 2013-05-29 | Reiterated | Canaccord Genuity | Buy | $54 to $90 |
| 2013-01-09 | Reiterated | Needham | Buy | $30 to $36 |
| 2012-10-18 | Reiterated | Needham | Buy | $22 to $30 |
| 2012-10-18 | Reiterated | Capstone Investments | Buy | $21 to $27 |
| 2012-10-12 | Initiated | Capstone Investments | Buy | $21 |
| 2011-11-09 | Initiated | Deutsche Bank | Buy | $19 |
| 2011-06-28 | Initiated | Global Hunter Securities | Buy | $23 |
| 2010-12-06 | Initiated | Collins Stewart | Buy | $16 |
| 2016-05-17 | Boost Price Target | Leerink Swann | Outperform | $6.00 to $15.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-02-26 | Reiterated Rating | Leerink Swann | Outperform | $31.00 to $15.00 |
| 2016-02-12 | Downgrade | Bank of America | Neutral to Underperform | $6.00 |
| 2016-02-12 | Downgrade | Bank of America Corp. | Neutral to Underperform | $6.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In AEGR 1 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| MANAGED ACCOUNT ADVISORS LLC | 7753 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Broadfin Healthcare Master Fund Ltd | 13.57% (4010291) | AEGR / FLML / MELA / MRTX / PETX / PGNX / QLTI / REPH / |
| PERCEPTIVE ADVISORS LLC | 9.56% (2823426) | ACRX / AEGR / ALDX / BIOD / FOLD / LJPC / PLCC / RPRX / VSAR / ZGNX / |
| ADVENT INTERNATIONAL CORP/MA Member of Group > 10% | 8.32% (2457879) | AEGR / COTV / FIVE / VNTV / |
| ADVENT INTERNATIONAL LLC Member of Group > 10% | 8.23% (2430765) | AEGR / FIVE / VNTV / |
| ADVENT HEALTHCARE & LIFE SCIENCES III LIMITED PARTNERSHIP Member of Group > 10% | 3.33% (985052) | AEGR / |
| Scheer David | 1.76% (521350) | ACHN / AEGR / TNGN / |
| Beer Marc D Chief Executive Officer | 0.27% (78631) | AEGR / NERV / |
| ALTA BIOPHARMA PARTNERS III LP | 0.19% (56190) | AEGR / CARA / CMRX / MGNX / SNSS / |
| Fitzpatrick Mark J. Chief Financial Officer | 0.03% (9500) | AEGR / |
| VANLENT ANNE | 0.01% (4000) | AEGR / AGTC / BOTA / OCRX / ONTX / QLTI / |
| SMITH SANDFORD D | 0.01% (2890) | AEGR / APRI / CUR / CYTK / QLTI / |
| Carter Martha J. Chief Regulatory Officer | 0.01% (1500) | AEGR / BIOD / |
UM